Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus.

Patyna S, Büttner S, Eckes T, Obermüller N, Bartel C, Braner A, Trautmann S, Thomas D, Geiger H, Pfeilschifter J, Koch A.

Prostaglandins Other Lipid Mediat. 2019 Oct;144:106348. doi: 10.1016/j.prostaglandins.2019.106348. Epub 2019 Jul 10.

PMID:
31301404
2.

Preanalytical Biases in the Measurement of Human Blood Sphingolipids.

Brunkhorst R, Pfeilschifter W, Patyna S, Büttner S, Eckes T, Trautmann S, Thomas D, Pfeilschifter J, Koch A.

Int J Mol Sci. 2018 May 7;19(5). pii: E1390. doi: 10.3390/ijms19051390.

3.

Incidence, Risk Factors, and Outcome of Acute Kidney Injury in Neurocritical Care.

Büttner S, Stadler A, Mayer C, Patyna S, Betz C, Senft C, Geiger H, Jung O, Finkelmeier F.

J Intensive Care Med. 2018 Jan 1:885066617748596. doi: 10.1177/0885066617748596. [Epub ahead of print]

PMID:
29378487
4.

Anatomy Revisited: Hemodialysis Catheter Malposition in the Left Ascending Lumbar Vein.

Büttner S, Patyna S, Rudolf S, Avaniadi D, Kaup M, Geiger H, Betz C.

Blood Purif. 2017;44(3):206-209. doi: 10.1159/000477755. Epub 2017 Jul 1.

PMID:
28668967
5.

Application of Hemoadsorption in a Case of Liver Cirrhosis and Alcohol-Related Steatohepatitis with Preexisting Hepatitis C Infection.

Büttner S, Patyna S, Koch B, Finkelmeier F, Geiger H, Sarrazin C, Farnik H.

Blood Purif. 2017;44(1):30-31. doi: 10.1159/000455064. Epub 2017 Feb 25. No abstract available.

6.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

PMID:
27836885
7.

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.

Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB.

Br J Cancer. 2013 Apr 16;108(7):1393-401. doi: 10.1038/bjc.2013.96. Epub 2013 Mar 19.

8.

Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats.

Coburn AM, Cappon GD, Bowman CJ, Stedman DB, Patyna S.

Birth Defects Res B Dev Reprod Toxicol. 2012 Aug;95(4):267-75. doi: 10.1002/bdrb.21012. Epub 2012 Apr 12.

PMID:
22499257
9.

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.

Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, Kang P.

Drug Metab Dispos. 2012 Mar;40(3):539-55. doi: 10.1124/dmd.111.042853. Epub 2011 Dec 16.

PMID:
22180047
10.

The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.

Hu-Lowe D, Brega N, Patyna S.

Mol Cancer Ther. 2011 Nov;10(11):2015. doi: 10.1158/1535-7163.MCT-11-0722. No abstract available.

11.

Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.

Blasi E, Heyen J, Patyna S, Hemkens M, Ramirez D, John-Baptiste A, Steidl-Nichols J, McHarg A.

Cardiovasc Ther. 2012 Oct;30(5):287-94. doi: 10.1111/j.1755-5922.2011.00278.x. Epub 2011 May 31.

PMID:
21884012
12.

Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.

Novello S, Camps C, Grossi F, Mazieres J, Abrey L, Vernejoux JM, Thall A, Patyna S, Usari T, Wang Z, Chao RC, Scagliotti G.

J Thorac Oncol. 2011 Jul;6(7):1260-6. doi: 10.1097/JTO.0b013e318219a973.

13.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P.

N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. Erratum in: N Engl J Med. 2011 Mar 17;364(11):1082.

14.

Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.

Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L.

Clin Cancer Res. 2009 Nov 15;15(22):7045-52. doi: 10.1158/1078-0432.CCR-09-1521. Epub 2009 Nov 10.

15.

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.

Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D.

Birth Defects Res B Dev Reprod Toxicol. 2009 Jun;86(3):204-13. doi: 10.1002/bdrb.20194.

PMID:
19294680
16.

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.

Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY.

Cancer Chemother Pharmacol. 2009 Sep;64(4):691-706. doi: 10.1007/s00280-008-0917-1. Epub 2009 Jan 25.

PMID:
19169880
17.

Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.

Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W.

Toxicol Pathol. 2008 Dec;36(7):905-16. doi: 10.1177/0192623308326151. Epub 2008 Nov 3.

PMID:
18981453
18.

Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.

Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA.

Toxicol Sci. 2008 Nov;106(1):153-61. doi: 10.1093/toxsci/kfn157. Epub 2008 Jul 29.

PMID:
18664550
19.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.

Mol Cancer Ther. 2006 Jul;5(7):1774-82.

20.

Supplemental Content

Loading ...
Support Center